ASCO GU Symposium Announces New Findings on Tumor Reduction and Survival Outcomes in Advanced Renal Cell Carcinoma
The latest analysis, presented Feb. 13-14 at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025), further solidifies the effectiveness of the lenvatinib (Lenvima) and pembrolizumab (Keytruda) combination in treating this aggressive form of kidney cancer. Hutson played a key role in the study and provided insights into the impact of these findings.
“This analysis reinforces that greater tumor shrinkage correlates with improved survival outcomes,” Hutson said. “We now have compelling evidence that reducing overall tumor burden not only extends survival but also enhances the effectiveness of subsequent treatments, setting patients up for better long-term prognoses.”
The study, which initially led to the FDA approval of lenvatinib plus pembrolizumab for advanced renal cell carcinoma in 2021, continues to provide valuable insights into treatment strategies. The new findings demonstrate that patients with greater reductions in total tumor size at disease progression had significantly longer median survival rates. Additionally, data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) show that patients receiving the combination therapy were more likely to maintain or improve their IMDC risk scores, further supporting the regimen’s impact on long-term survival.
“These findings emphasize the importance of aggressive tumor reduction in the fight against renal cell carcinoma,” Hutson added. “The data suggest that this combination therapy offers the best outcomes among currently available treatments, making it a strong contender for first-line treatment in advanced renal cell carcinoma.”
TTUHSC and UMC Health System remain committed to advancing cancer treatment and improving patient outcomes through innovative research and clinical excellence.
About Texas Tech University Health Sciences Center
TTUHSC is a medical education, research and patient care leader dedicated to improving health outcomes across Texas and beyond.
About UMC Health System
UMC Health System is a nationally recognized academic medical center committed to delivering advanced patient care, innovative research and comprehensive cancer treatment.
Related Stories
TTUHSC School of Medicine Resident Making an Impact as Published Researcher
During the current fiscal year, Pojsakorn Danpanichkul, M.D., has contributed to 19 papers in high-impact journals, including nine on which he served as first author.
Transformative, Collaborative Gift to Accelerate Research on Urinary Tract Infections
Eliese Teasdale recently made a $975,000 gift to the TTUHSC School of Nursing to support ongoing research focusing on detection and treatment of urinary tract infections (UTIs) in women.
Logsdon Receives Grant to Study Vascular Side of Traumatic Brain Injuries
Supported by a three-year, $578,211 grant from the National Institutes of Health-National Institute on Aging, Aric F. Logsdon, Ph.D., will study how brain endothelial cells, or blood vessels within the brain, handle the stressors of neuroinflammation.
Recent Stories
TTUHSC School of Medicine Resident Making an Impact as Published Researcher
During the current fiscal year, Pojsakorn Danpanichkul, M.D., has contributed to 19 papers in high-impact journals, including nine on which he served as first author.
Legislative Support Strengthens Texas Tech University Health Sciences Center’s Efforts to Improve Rural Cancer Care
Support for TTUHSC continued in the 89th legislative session, including $25 million to establish the Rural Cancer Collaborative.
TTUHSC’s Affordable Medical Education Empowers West Texas Students to Serve
On Friday, July 25, students marked a defining moment in their journey at the White Coat Ceremony, symbolizing not only the start of their medical education but also their dedication to the communities that shaped them.